Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
Xarelto
Generic name / active ingredient
rivaroxaban
Dosage-form class
Dosage form and presentation as documented in the linked primary label
Route
Oral
Record reviewed
2026-08-24

Copy from the pack in hand

Source-linked reading points

  • Check XARELTO, the generic name rivaroxaban, per-tablet strength, oral-tablet form, NDC, package count and target market together. The 2.5 mg/60-tablet bottle and the 10 mg, 15 mg and 20 mg/30-tablet bottles are distinct label identities; none of these numbers establishes a person's condition, course, daily use or interchangeability with another medicine.
  • Anticoagulant-related medicines must not be self-switched, combined, made up after a missed dose or temporarily stopped merely because they are all described as preventing clots. For a switch, missed use, symptoms or a procedure, contact the prescribing team or pharmacist with the complete medicine list.
  • Anti-inflammatory pain medicines, antiplatelet or other clotting-related products, and any newly added prescription, OTC, supplement or herb all need joint review. Do not treat one interaction note on a webpage as an instruction to start or stop any medicine.
  • Appearance and label images serve source checking only. Strength, market, packaging form and label version can differ; an image cannot authenticate a product, confirm a current label or replace clinical instructions around bleeding or procedures.

Reviewed presentation examples — compare every field

  • 2.5 mg per tablet; 60-tablet bottleNDC 50458-577-60
  • 10 mg per tablet; 30-tablet bottleNDC 50458-580-30
  • 15 mg per tablet; 30-tablet bottleNDC 50458-578-30
  • 20 mg per tablet; 30-tablet bottleNDC 50458-579-30

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-24
Source record
3 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image